Cervical cancer: FIGO staging and treatment in outline
- Disorder
Cervical cancer is preventable, yet it still kills many young women in Colombia. Caught small it is cured by surgery; larger, by radiotherapy with chemotherapy.
See it in 3D: Cervix · Vagina · Ureters · Uterine artery · Obturator nodes
What it is
Cervical cancer is caused almost always by persistent high-risk human papillomavirus infection; most are squamous cell carcinomas; adenocarcinoma is the next most common type and its share is rising in some countries. It grows locally into the vagina and the parametria (the tissue beside the cervix that carries the ureters and vessels), spreads to pelvic then para-aortic nodes, and late to distant organs. It is staged with the FIGO 2018 system, which uses examination, imaging and pathology. In outline, small early cancers are treated with surgery, locally advanced cancers with chemoradiation and brachytherapy, and metastatic disease with systemic treatment. It remains one of the leading causes of cancer death in women in Latin America, concentrated where screening and treatment are hardest to reach.
How to recognise it
- Early cancer is often silent; symptoms are bleeding after intercourse, between periods or after menopause, and a watery or bloody discharge.
- Late signs: pelvic or back pain, leg swelling, kidney failure from ureteric obstruction, and bleeding or fistula into bladder or rectum.
- Diagnosis is by biopsy of a visible lesion or after an abnormal screening test; a smear is not used to investigate a visible lesion.
- Staging uses examination, MRI of the pelvis and PET-CT or CT for nodes and distant spread where available.
- Hydronephrosis from tumour is at least stage IIIB, whatever the size of the primary.
FIGO 2018 staging and the usual treatment in outline
| Stage | Extent | Usual treatment |
|---|---|---|
| IA | Microscopic: invasion up to 5 mm deep (IA1 under 3 mm, IA2 3–5 mm) | Cone biopsy or simple hysterectomy (IA1); radical surgery or trachelectomy with nodes (IA2) |
| IB | Confined to the cervix, deeper or visible: IB1 up to 2 cm, IB2 2–4 cm, IB3 over 4 cm | IB1–IB2: radical hysterectomy with pelvic nodes (trachelectomy for fertility in small tumours); IB3: chemoradiation |
| II | Beyond the uterus: IIA upper two-thirds of the vagina; IIB the parametria, not the pelvic wall | Chemoradiation with brachytherapy (small IIA may have surgery) |
| III | Lower third of the vagina (IIIA), pelvic wall or hydronephrosis (IIIB), pelvic or para-aortic nodes (IIIC1, IIIC2) | Chemoradiation with brachytherapy, extended field for para-aortic nodes |
| IV | Bladder or rectal mucosa (IVA) or distant organs (IVB) | IVA: chemoradiation; IVB: systemic treatment and palliative care |
Differential and risks
- Differential of a cervical lesion or abnormal bleeding: cervical polyp, ectropion, cervicitis, endometrial cancer extending to the cervix, and metastases.
- Radical hysterectomy removes the uterus, upper vagina and parametria with the pelvic nodes; open surgery gives better survival than the minimally invasive approach in early disease.
- Chemoradiation combines external beam radiotherapy with cisplatin-based chemotherapy, then brachytherapy to the cervix; completing it in time matters for cure.
- Metastatic or recurrent disease is treated with platinum-based chemotherapy, often with bevacizumab or immunotherapy where available, and with early palliative care.
- Side effects of treatment include early menopause after radiotherapy, vaginal stenosis, bladder and bowel damage and lymphoedema.
Next step / Initial management
- Any visible cervical lesion or post-coital bleeding with an abnormal-looking cervix: biopsy or urgent colposcopy, not a repeat smear.
- Confirmed cancer: refer to a gynaecological oncology unit for staging (examination, pelvic MRI, CT or PET-CT) and a multidisciplinary plan.
- Check kidney function and the ureters, and treat anaemia before radiotherapy.
- Follow-up after treatment: regular review for recurrence, sexual health, vaginal dilators after radiotherapy and hormone replacement where appropriate.
- Prevention still matters for her family: HPV vaccination of daughters and sons and screening of other women.
Common traps
- Taking a screening smear from a visible lesion: screening is for women without symptoms; a lesion needs a biopsy.
- Assuming a small tumour is early stage when the kidneys are obstructed: hydronephrosis makes it at least IIIB.
- Thinking surgery is always better than radiotherapy: for bulky or parametrial disease chemoradiation is the standard and adding a hysterectomy adds harm.
- Forgetting that a vaccinated woman can still develop cervical cancer: vaccines do not cover every high-risk type.
Test yourself
Think of the answer, then tap the question to see it.
A woman has a 3-centimetre cancer confined to the cervix and normal imaging. What stage is it and what is the usual treatment?
Stage IB2; usually radical hysterectomy with pelvic lymph node assessment (or chemoradiation as an alternative).
A small cervical cancer causes bilateral hydronephrosis. What stage is it, and why?
At least stage IIIB: tumour reaching the pelvic wall or blocking a ureter defines IIIB regardless of the primary's size.
Why is chemoradiation preferred to surgery for stage IIB cervical cancer?
The tumour has reached the parametria, so surgery cannot remove it with clear margins; pelvic radiation with cisplatin treats the cervix, parametria and nodes together.
Elsewhere in DurgiPedia
- Invasive cervical carcinoma
- HPV and cervical carcinogenesis
- Taking a cervical cytology or HPV sample and assisting the pelvic examination
Connections
See it in 3D5
The structures of Durgical's 3D anatomy where it is found.
Microorganisms1
In Pharmacology3
← All of obstetrics and gynaecology
Educational content; it does not replace assessment by a doctor or your institution's protocols, and it contains no doses. For heavy bleeding, a severe headache or blurred vision, a seizure, fever, strong abdominal pain or fewer baby movements, go to an emergency department at once.
Sources: Cervical Cancer (StatPearls Publishing (NCBI Bookshelf), 2023); Cervical Cancer Treatment (PDQ®), health professional version (National Cancer Institute, 2025); Cervical cancer (fact sheet) (World Health Organization, 2025); Cervical cancer mortality among young women in Latin America and the Caribbean: trend analysis from 1997 to 2030 (BMC Public Health (Europe PMC), 2022).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
